Jonathan Zalevsky - Aug 19, 2025 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Role
Chief R&D Officer
Signature
Mark A. Wilson
Stock symbol
NKTR
Transactions as of
Aug 19, 2025
Transactions value $
-$19,278
Form type
4
Date filed
8/21/2025, 09:05 PM
Previous filing
May 21, 2025
Next filing
Sep 4, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Zalevsky Jonathan Chief R&D Officer C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BLVD SOUTH, SAN FRANCISCO Mark A. Wilson 2025-08-21 0001789857

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NKTR Common Stock Sale -$19.3K -725 -3.56% $26.59 19.7K Aug 19, 2025 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NKTR Stock Option Award $0 +16.7K $0.00 16.7K Aug 19, 2025 Common Stock 16.7K $0.50 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.
F2 This transaction was executed in multiple trades at prices ranging from $26.19 to $27.15 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
F3 On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.
F4 These stock options were granted on December 13, 2023 under the 2017 Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of three years from the date of grant.
F5 The Organization and Compensation Committee of the Board of Directors of the Issuer determined on July 17, 2025 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on August 19, 2025 (subject to remaining time-based vesting requirements).